Logo

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma

Share this

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma

Shots:

  • The P-III LIBERTY ASTHMA VOYAGE study involves assessing of Dupixent (SC- 100/200mg- q2w ) + SOC maintenance therapy of medium-dose ICS with a second controller medication/ high-dose ICS with/out second controller medication vs PBO in 408 children 6 to <12 years old with uncontrolled moderate-severe asthma
  • Results: Patients with baseline blood EOS ≥300 cells/μl and patients with markers of type 2 inflammation (FeNO ≥20 ppb or EOS ≥150 cells/μl)- reduction in the rate of asthma attacks- with 65% & 59% average reduction over 1yr. (0.24 and 0.31 vs 0.67 and 0.75 events/year)- improvement in lung function @12wks. (10.15 and 10.53 vs 4.83 and 5.32); improvement in lung function was observed as early as 2wks.and was sustained for up to 52wks. respectively
  • Dupixent is a mAb that inhibits the signaling of the IL-4 & IL-13 proteins with its expected regulatory submissions in the US & EU for children aged 6-11 yrs. in Q1’21

     ­ Ref: GlobeNewswire | Image: BioPharma Reporter
Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions